Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

Transcription profiling of non squamous cell lung cancer cell lines to investigate sensititivity to gefitinib and predict this in previously untested cell lines

ABSTRACT: Eleven NSCLC cell lines with widely divergent gefitinib sensitivities were compared using gene expression. Genes associated with gefitinib response were used to classify additional NSCLC lines with unknown gefitnib sensitivity. A subset of the test set data was tested for gefitinib sensitivity, and results correlated strongly with the gene expression-based predictions; All eleven training set lines, and seven test set lines had both HGU133A and B chips done, while other test set lines had only HGU133As. Experiment Overall Design: Baseline (unstimulated) gene expression was measured in a large panel of NSCLC cell lines.

ORGANISM(S): Homo sapiens

SUBMITTER: Christopher Coldren

PROVIDER: E-GEOD-4342 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Publications

Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.

Coldren Christopher D CD Helfrich Barbara A BA Witta Samir E SE Sugita Michio M Lapadat Razvan R Zeng Chan C Barón Anna A Franklin Wilbur A WA Hirsch Fred R FR Geraci Mark W MW Bunn Paul A PA

Molecular cancer research : MCR 20060801 8

Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) produce objective responses in a minority of patients with advanced-stage non-small cell lung cancer (NSCLC), and about half of all treated patients progress within 6 weeks of instituting therapy. Because the target of these agents is known, it should be possible to develop biological predictors of response, but EGFR protein levels have not been proven useful as a predictor of TKI response in patients and the mechani ...[more]

PMID: 16877703

Dataset Information

Transcription profiling of non squamous cell lung cancer cell lines to investigate sensititivity to gefitinib and predict this in previously untested cell lines

Publications

Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Similar Datasets

Gefitinib sensitivity in NSCLC cell lines
2006-08-31 | GSE4342 | GEO

miRNA expression of gefitinib-resistant cell lines
2018-02-21 | GSE110815 | GEO

Comparison of receptor tyrosine kinase (RTK) family gene expression between normoxic cells and hypoxia-induced gefitinib resistant clones
2020-12-19 | E-MTAB-9452 | biostudies-arrayexpress

JUN-Mediated downregulation of EGFR signaling is associated with resistance to gefitinib in EGFR-mutant NSCLC cell lines [ChIP-seq]
2017-06-02 | GSE95590 | GEO

JUN-Mediated downregulation of EGFR signaling is associated with resistance to gefitinib in EGFR-mutant NSCLC cell lines [RNA-seq]
2017-06-02 | GSE95558 | GEO

miRNA expression of gefitinib-resistant cell lines
| PRJNA434645 | ENA

Transcriptomic analysis of gefitinib-resistant EGFR-mutant NSCLC cells
2019-12-31 | GSE123066 | GEO

Human colon cancer cell lines: NT(untreated) vs EGF, Cetuximab and Gefitinib treatments
2007-09-12 | GSE8967 | GEO

NSCLC cells treated with Gefitinib
2011-01-27 | E-GEOD-23206 | biostudies-arrayexpress